MedTrace Logo

Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704

NCT00692042 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2008-06-24

No results posted yet for this study

Summary

The primary aim for this study is to investigate the safety and tolerability of the AZD1704, first time in man.

Conditions

Interventions

DRUG

AZD1704

One dose, by mouth

Sponsors & Collaborators

Principal Investigators

  • Billy Fahy, MD · AstraZeneca R&D CPU Nottingham, UK

  • Lars Ståhle, MD · AstraZeneca R&D Södertälje, Sweden

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00692042 on ClinicalTrials.gov